Mobile

Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Studie fáze 4 s Brentuximab Ve...

Update Il y a 4 ans
Reference: EUCTR2013-000232-10

Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Studie fáze 4 s Brentuximab Vedotinem u pacientů s relabujícím nebo refrakterním Hodgkinovým lymfomem, kteří nejsou vhodní k transplantaci kmenových buněk nebo multiagentní chemoterapii

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the antitumor efficacy, as determined by the objective response rate (ORR) of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, in patients with relapsed or refractory classical HL who are considered to be not suitable for SCT or multiagent chemotherapy

Inclusion criteria

  • relapsed or refractory Hodgkin Lymphoma

Links